• 제목/요약/키워드: Cardiac ischemia

검색결과 181건 처리시간 0.025초

허혈 전처치가 심근보호에 미치는 영향 - 적출 쥐 심장에서 상온에서의 심근허혈과 중등도 저체온하에서 심근정지액 사용 시의 비교 연구 - (Effect of Ischemic Preconditioning on Myocardial Protection - A Comparative Study between Normothermic and Moderate Hypothermic Ischemic Hearts Induced by Cardioplegia in Rats -)

  • 조성준;황재준;김학제
    • Journal of Chest Surgery
    • /
    • 제36권5호
    • /
    • pp.242-254
    • /
    • 2003
  • 배경: 상온에서 단기간의 심근 허혈이 가해질 때 허혈 전처치가 심근기능의 보호에 효과가 있다는 사실은 어느 정도 증명되었지만 저온의 심근 보호액을 이용하여 심장을 정지시킨 후 $25^{\circ}C$의 중등도 저체온 상태에서 간헐적으로 심근 보호액을 주인하며 장시간 허혈 상태에 노출시키는 일반적인 심장수술을 시행하는 경우에 허혈 전처치가 효과가 있는지에 대해서는 연구가 부족한 상태이며 또한 연구결과에 따라 많은 이견이 있다. 본 실험에서는 상온에서의 허혈과 중등도 저체온법을 사용하며 심근보호액의 간헐적 주입을 병행하는 일반 심장 수술에서 허혈 전처치가 심근 보호에 미치는 효과를 비교하기 위해 실험을 진행하였다. 대상 및 방법: $25^{\circ}C$에서 St. Thomas hospital 심근 보호액을 사용한 경우와 상온에서 심근 보호액 없이 허혈을 받은 경우 각각에서 허혈 전처치의 효과를 비교하였다. 모든 군의 심장을 20분간 37$^{\circ}C$의 Krebs 용액으로 관류시키고, 제1군은(n=6)은 허혈 전처치로 37$^{\circ}C$에서 3분간의 허혈 및 5분간 재관류를 두 차례 받은 후, 4$^{\circ}C$의 심근 보호액을 20분마다 반복해 주입하며 120분간 $25^{\circ}C$의 중등도 저체온 상태를 유지하였다. 제2군(n=6)은 제1군에 대한 대조군으로 허혈 전처치를 하지 않은 상태에서 역시 120분간 $25^{\circ}C$상태를 유지하며 20분마다 심근 보호액을 반복해 주었다. 제1, 2군 모두 허혈기가 끝난 후 37$^{\circ}C$의 Krebs 용액으로 30분간 재관류하며 결과를 측정하였다(제1, 2군:저온 심근 보호액군).상온에서의 허혈군으로 37$^{\circ}C$를 유지하며 전반적 허혈을 받은 두 군을 설정하였다. 제3군(n=6)은 3분 허혈, 5분 재관류로 허혈 전처치 후 37$^{\circ}C$에서 30분간 허혈 상태를 유지 후 30분간 재관류하였고, 제4군(n=6)은 제3군에 대한 대조군으로 허혈 전처치 엄이 30분간 허혈 후 30분간 재관류하며 결과를 측정하였다(제3, 4군: 상온 심정지군). 걸과: 저온 심근 보호액 군에서는 허혈전처치를 시행 후 심근 보호액을 주입한 군(제1군)과 허혈 전처치 없이 심근 보호액을 주입한 대조군(제2군)의 비교에서 관상동맥 관류량, 심박동수, 좌심실내압, 좌심실압과 맥박수를 곱한 값, 좌심실압순간 변화율 및 CPK, LDH의 비교 모두에서 총계적으로 유의한 차이를 볼 수 없었다(p=NS). 상온 심정지 군에서는 허혈 전처치 후 37$^{\circ}C$에서 허혈을 유지한 군(제3군)과 허혈 전처치 없이 허혈을 유지한 대조군(제4군)의 비교에서 허혈 전처치를 시행한 군이 좌심실 수축기압, 좌심실압과 맥박수를 곱한 값, 좌심실 이완기압, 좌심실압 순간 변화율 등이 허혈 전처치를 시행치 않은 군보다 유의하게 호전되었고 CPK, LDH의 변화에서도 유의한 차이를 보여 허혈 전처치가 심근의 기능적 회복 및 심근 보호에 효과가 있음을 보았다(p<0.05). 결론: 이상의 결과에서 쥐의 심장을 이용한 실험 시 허혈 전처치가 상온에서의 심근 허혈과 재관류 시에는 심근기능 회복에 효과가 있으나 중등도 저체온법과 간헐적 심근 보호액의 주입 하에서 시행한 심장의 재관류에는 심근보호 효과가 없음을 보았다.

Postmortem mRNA Expression Patterns in Left Ventricular Myocardial Tissues and Their Implications for Forensic Diagnosis of Sudden Cardiac Death

  • Son, Gi Hoon;Park, Seong Hwan;Kim, Yunmi;Kim, Ji Yeon;Kim, Jin Wook;Chung, Sooyoung;Kim, Yu-Hoon;Kim, Hyun;Hwang, Juck-Joon;Seo, Joong-Seok
    • Molecules and Cells
    • /
    • 제37권3호
    • /
    • pp.241-247
    • /
    • 2014
  • Sudden cardiac death (SCD), which is primarily caused by lethal heart disorders resulting in structural and arrhythmogenic abnormalities, is one of the prevalent modes of death in most developed countries. Myocardial ischemia, mainly due to coronary artery disease, is the most common type of heart disease leading to SCD. However, postmortem diagnosis of SCD is frequently complicated by obscure histological evidence. Here, we show that certain mRNA species, namely those encoding hemoglobin A1/2 and B (Hba1/2 and Hbb, respectively) as well as pyruvate dehydrogenase kinase 4 (Pdk4), exhibit distinct postmortem expression patterns in the left ventricular free wall of SCD subjects when compared with their expression patterns in the corresponding tissues from control subjects with non-cardiac causes of death. Hba1/2 and Hbb mRNA expression levels were higher in ischemic SCD cases with acute myocardial infarction or ischemic heart disease without recent infarction, and even in cardiac death subjects without apparent pathological signs of heart injuries, than control subjects. By contrast, Pdk4 mRNA was expressed at lower levels in SCD subjects. In conclusion, we found that altered myocardial Hba1/2, Hbb, and Pdk4 mRNA expression patterns can be employed as molecular signatures of fatal cardiac dysfunction to forensically implicate SCD as the primary cause of death.

선천성 심기형 환아에서 체외순환후 혈청 및 소변 Amylase치의 변화 (The Change of Derum and Urine Amylase Level Following Cardiopulmonary Bypass in the Patients with Congenital heart disease)

  • 백희종;김용진
    • Journal of Chest Surgery
    • /
    • 제28권10호
    • /
    • pp.892-899
    • /
    • 1995
  • Pancreatitis is a known complication of cardiac surgery with cardiopulmonary bypass. Although ischemia is believed to be a factor, the exact cause of pancreatitis after cardiopulmonary bypass remains unknown.We prospectively studied 67 consecutive patients undergoing cardiac surgery with cardiopulmonary bypass for evaluation of the pancreatic injury after cardiopulmonary bypas. Serial measurement of amylase level in serum and urine was done postoperatively. Hyperamylasemia was detected in 15 patients[22.4% , of whom no patient had pancreatitis. There was no significant difference between serum amylase level and parameters such as cardiopulmonay bypass time, aortic cross clamp time, mean blood pressure, rectal temperature, flow rate, and use of circulatory arrest during cardiopulmonary bypass. Hyperamylasuria was detected in 8 patients[11.9% , and urine amylase level was elevated significantly in the groups with prolonged cardiopulmonary bypass, mean blood pressure more than 40mmHg, and rectal temperature more than 20 $^{\circ}$C. We recommend that serum amylase level and/or amylase-creatinine clearance ratio is measured for ealy detection and management of pancreatitis after cardiopulmonary bypass.

  • PDF

심장판막질환과 동반된 관상동맥질환의 수술 (Cardiac Valve Replacement and Simultaneous Myocardial Revascularization)

  • Reiner, Korfer;Jee, Heng-Ok
    • Journal of Chest Surgery
    • /
    • 제21권1호
    • /
    • pp.164-168
    • /
    • 1988
  • Between November, 1984, and May, 1986, 93 patients underwent combined valvular and coronary artery operation. They were 70 male and 23 female, the age ranging from 29 to 82. From this population 89 patients underwent single valve replacement and 4 patients underwent double valve replacement. Patients with mitral valve disease were in the majority present in the age group between 50 till 70, where as in the group after 60 years, patients with aortic valve disease were dominant. The main indication for aortic valve replacement was aortic stenosis and the indication for mitral valve replacement was equal between mitral stenosis and mitral incompetence, the later was due to papillary dysfunction after myocardial infarction. Dyspnea was a very frequent symptom and it was found in nearly all patients. 28 patients had a previous myocardial infarction and severe left ventricular dysfunction. The grafts were placed prior to valve replacement and periods of myocardial ischemia were kept at a minimum by maintaining coronary perfusion throughout the operation. It is our opinion that simultaneous valve replacement and myocardial revascularization does not increase the risk of cardiac valve replacement substantially.

  • PDF

Pathophysiological Roles of AMP in Hypertrophied Heart

  • Chunhua Cao;Han, Jeong-Hee;Kim, Sung-Zoo;Cho, Kyung-Woo;Kim, Suhn-Hee
    • 한국생물물리학회:학술대회논문집
    • /
    • 한국생물물리학회 2003년도 정기총회 및 학술발표회
    • /
    • pp.31-31
    • /
    • 2003
  • Cardiac atrium is now well-known as an endocrine organ which secretes atrial natriuretic peptide (AMP), participating in the regulation of body fluid and blood pressure. ANP is released mainly from cardiac muscle cells in response to various physiological and pathological conditions to induce atrial stretch. Ca$\^$2+/ may be one of the most important factors affecting ANP secretion even though controversy still persists. The aim of the present study is to investigate the effect of lysophosphatidylcholines (LPCs) and moxonidine on atrial hemodynamics and ANP secretion in hypertrophied atria. LPC is an endogenous phospholipid released from cell membrane during ischemia, and moxonidine is a imidazoline 1 (Il) receptor agonoist.

  • PDF

Troponin-Positive Non-Obstructive Coronary Arteries and Myocardial Infarction with Non-Obstructive Coronary Arteries: Definition, Etiologies, and Role of CT and MR Imaging

  • Seung Min Yoo;Sowon Jang;Jeong A Kim;Eun Ju Chun
    • Korean Journal of Radiology
    • /
    • 제21권12호
    • /
    • pp.1305-1316
    • /
    • 2020
  • In approximately 10% of patients with acute myocardial infarction (MI), angiography does not reveal an obstructive coronary stenosis. This is known as myocardial infarction with non-obstructive coronary arteries (MINOCA), which has complex and multifactorial causes. However, this term can be confusing and open to dual interpretation, because MINOCA is also used to describe patients with acute myocardial injury caused by ischemia-related myocardial necrosis. Therefore, with regards to this specific context of MINOCA, the generic term for MINOCA should be replaced with troponin-positive with non-obstructive coronary arteries (TpNOCA). The causes of TpNOCA can be subcategorized into epicardial coronary (causes of MINOCA), myocardial, and extracardiac disorders. Cardiac magnetic resonance imaging can confirm MI and differentiate various myocardial causes, while cardiac computed tomography is useful to diagnose the extracardiac causes.

NO 억제제가 허혈전처치의 심장 보호효과에 미치는 영향 (Effect of Inhibitor of Nitric Oxide Synthesis on the Ischemic Reconditioning in Isolated Heart of Rat.)

  • 유호진;조은용
    • Journal of Chest Surgery
    • /
    • 제29권8호
    • /
    • pp.807-815
    • /
    • 1996
  • 허혈전처치(ischemic preconditioniiIE)의 허혈심장 보호효과와 그 기전을 규명하기 위한 일환으로 citric oxide(HO)가 허혈전처치의 심보호 효과에 미치는 영향을 검토하였다. 흰쥐 적출심장의 Langendorrr관류표본에서 실험적인 허할(30분)-재관류(30분) 손상을 유도하였고, 허혈전처치는 재관류손상 유도 전에 5분 허혈 - 5분 재관류를 3회 반복하여 시행하였다. 허혈심근 손상의 지표로 심수축기능 세질효소 유출 및 미세형태학적 변화를, 그리고 HO 합성 억제제인 L-HAME 를 투여하여 허혈전처치와 비전처치 허혈-재관류 심장들에서 손상의 정도를 비교하였다. 그 결과 허혈- 재관류 심장에서 심기능의 저하및 세포질 유출이 현저하게 증가하였고 전자현미경상의 미세구조에서도 세포내 소기관 및 myofibril의 파괴가 관찰되 어 심근손상이 심함을 알 수 있었다. 허 혈-재관류에 의한 심 장손상은 허혈전처치를 시행한 허혈-재관류 심장에서는 현격하게 감소돼 심회복률이 77%로 증가하였 고 세포질유출도 현저하게 감소되었으며 미세소견에서도 세포구조가 비교적 잘 보존되었다. 허혈전처 치에 의한 심보호 효과에 NO가 관여하는지를 관찰하기 위하여 NO합성 억제제인 L-NAME를 투여하 여 허혈전처치를 시행하였다. 결과 L-UAME투여로 허혈전처치에 의하여 회복된 심기능 및 LDH유출 감소에 아무런 영향을 주지 않았고 허혈전처치에 의하여 비교적 잘 보존된 미세구조 역시 영향을 받지 않았다. 이상의 결과들로부터 허혈전처치는 세포수준에서 허혈심근의 재관류손상을 방지하며, NO합성의 증가가 횐쥐 적출 심장에서 허혈전처치에 의한 허혈심장 보호효과에 크게 기여하지 않을 것으로 사료되었다.

  • PDF

The optimal model of reperfusion injury in vitro using H9c2 transformed cardiac myoblasts

  • Son, Euncheol;Lee, Dongju;Woo, Chul-Woong;Kim, Young-Hoon
    • The Korean Journal of Physiology and Pharmacology
    • /
    • 제24권2호
    • /
    • pp.173-183
    • /
    • 2020
  • An in vitro model for ischemia/reperfusion injury has not been well-established. We hypothesized that this failure may be caused by serum deprivation, the use of glutamine-containing media, and absence of acidosis. Cell viability of H9c2 cells was significantly decreased by serum deprivation. In this condition, reperfusion damage was not observed even after simulating severe ischemia. However, when cells were cultured under 10% dialyzed FBS, cell viability was less affected compared to cells cultured under serum deprivation and reperfusion damage was observed after hypoxia for 24 h. Reperfusion damage after glucose or glutamine deprivation under hypoxia was not significantly different from that after hypoxia only. However, with both glucose and glutamine deprivation, reperfusion damage was significantly increased. After hypoxia with lactic acidosis, reperfusion damage was comparable with that after hypoxia with glucose and glutamine deprivation. Although high-passage H9c2 cells were more resistant to reperfusion damage than low-passage cells, reperfusion damage was observed especially after hypoxia and acidosis with glucose and glutamine deprivation. Cell death induced by reperfusion after hypoxia with acidosis was not prevented by apoptosis, autophagy, or necroptosis inhibitors, but significantly decreased by ferrostatin-1, a ferroptosis inhibitor, and deferoxamine, an iron chelator. These data suggested that in our SIR model, cell death due to reperfusion injury is likely to occur via ferroptosis, which is related with ischemia/reperfusion-induced cell death in vivo. In conclusion, we established an optimal reperfusion injury model, in which ferroptotic cell death occurred by hypoxia and acidosis with or without glucose/glutamine deprivation under 10% dialyzed FBS.

Angiotensin II $AT_1$ 수용체 길항제인 SK-1080의 적출심장에 대한 허혈후 재관류시의 작용 및 혈소판응집과 혈액응고에 대한 효과 (Effects of the AngiotensinII $AT_1$ Receptor Antagonist SK-1080 on Ischemia/reperfusion in Isolated Rat Hearts and on Platelet Aggregation and Coagulation in Human Blood)

  • 우수경;최상수;이병호;권광일
    • 약학회지
    • /
    • 제44권6호
    • /
    • pp.558-565
    • /
    • 2000
  • SK-1080 is one of the newly developed orally active nonpeptide angiotensinII $AT_1-receptor$ antagonist that selectively acts at $AT_1$ receptor with high affinity. The cardiac effect on ischemia/reperfusion injury of SK-1080 was compared with those of losartan, a prototype of this class, in isolated rat hearts. Isolated perfused rat heart was pretreated with drug for 10 min and then subjected to global ischemia for 30 min followed by reperfusion with- or without drug for 30 min. The possible additive effect of SK-1080 on the platelet aggregation and coagulation in human blood was also studied. We investigated whether SK-1080 effects the platelet aggregation induced by ADP, a platelet agonist partially dependent on $thromboxaneA_2$. The clotting times in the prothrombin time (PT) and activated partial thromboplastin time (APTT) were also examined in human plasma in vitro as coagulation screening test. SK-1080 improved reperfusion function (LVDP, left ventricular developed pressure; PRP, rate-pressure product) in a dose-dependent manner. SK-1080 reduced ADP-induced platelet aggregation compared with vehicle but less than losartan, and did not affect clotting times.

  • PDF